• Derek J. Maetzold, President and Chief Executive Officer, reported option exercises totaling 22,902 shares at USD 2.39 on Aug. 4-5.
• He reported sales totaling 41,357 shares at weighted-average prices of about USD 30.68 to USD 31.34 over the same period.
• Directly held common stock ended at 21,479 shares following the transactions.

Disclaimer: This news brief was created by Public Technologies (PUBT) using generative artificial intelligence. While PUBT strives to provide accurate and timely information, this AI-generated content is for informational purposes only and should not be interpreted as financial, investment, or legal advice. Castle Biosciences Inc. published the original content used to generate this news brief via EDGAR, the Electronic Data Gathering, Analysis, and Retrieval system operated by the U.S. Securities and Exchange Commission (Ref. ID: 0001628280-26-054334), on August 06, 2026, and is solely responsible for the information contained therein.